Anthropic IPO Could Challenge SpaceX’s Record $86 Billion Offering 
Hanmi Pharm Soars 30% on $2.3 Billion Genentech Obesity Drug Deal 
Unifor Reaches Tentative GM Deal for 4,600 Ontario Workers 
Tokio Marine Eyes Multibillion-Dollar Suncorp Takeover 
KPMG Australia Cuts 5% of Workforce Amid Scandal 
Bathla Group Hires Administrators as Australia Housing Slump Deepens 
Woodside Drops $5 Billion Clean Energy Plan as Profit Rises 7% 
SEC Probes Banks Over Situational Awareness Hedge Fund Collapse 
China EV Stocks Slide as Door Handle Recall Hits 4.3 Million Vehicles 
California Seeks Paramount Divestitures in Warner Bros. Merger 
Luxshare Shares Rise as First-Half Profit Jumps 18% 
Trump Buys SpaceX Shares After Record IPO 
Xiaomi Unveils Xring O3 Chip for Flagship Foldable Phone 
Tesla Raises Cybertruck Prices by $5,000 in US 
Nvidia AI Server Prices Set to Rise as Memory Costs Surge 
Amazon to Expand Drone Delivery to 500 U.S. Locations 
SK Hynix Shares Fall as Workers Reject Wage Deal 
Add as a preferred source on Google
NEW YORK, May 02, 2018 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Edge Therapeutics, Inc. ("Edge Therapeutics") (NASDAQ:EDGE) between December 29, 2017 and March 27, 2018. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the District of New Jersey. To get more information go to:
http://www.zlk.com/pslra-d/edge-therapeutics-inc?wire=3
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that throughout the class period Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) Edge Therapeutics lead product candidate EG-1962 would likely fail a futility analysis in connection with the NEWTON 2 study; and (2) as a result of the foregoing, the Company's financial statements and Defendants' statements about Edge's business, operations, and prospects, were materially false and misleading at all relevant times.
If you suffered a loss in Edge Therapeutics you have until June 22, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street - 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com
